Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06652152
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-21
Brief Title:
Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP CR-CHOP Regimen in the Treatment of BCL2MYC Protein Double Expressor Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Mechanism Investigation of Rituximab Cyclophosphamide Doxorubicin Vincristine Prednisone R-CHOP Regimen or Tucidinostat Plus R-CHOP CR-CHOP Regimen in the Treatment of BCL2MYC Protein Double Expressor Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DEL Biomarker
Brief Summary:
This study is trying to explore the mechanism of R-CHOP regimen or tucidinostat plus R-CHOP CR-CHOP regimen in the treatment of BCL2MYC protein double expressor lymphoma
Detailed Description:
Tucidinostat formerly known as chidamide is an oral subtype-selective histone deacetylase inhibitor This study is trying to explore the mechanism of R-CHOP regimen or tucidinostat plus R-CHOP CR-CHOP regimen in the treatment of BCL2MYC protein double expressor lymphoma We will retain the hematoxylin and eosin HE -stained slides of tumor tissue immunohistochemical staining slides for BCL2 and MYC as well as FFPE Formalin Fixed Paraffin Embedded tissues We will conduct biological tests via digital pathology and DNA sequencing aiming to uncover the pathogenic mechanism of double expressor lymphoma and the potential therapeutic targets of CR-CHOP regimen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None